Soumit Roy
Stock Analyst at Jones Trading
(2.67)
# 2,164
Out of 5,005 analysts
43
Total ratings
28.12%
Success rate
3.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Soumit Roy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Initiates: Buy | $50 | $39.82 | +25.57% | 1 | Sep 8, 2025 | |
| TARA Protara Therapeutics | Initiates: Buy | $21 | $4.96 | +323.39% | 1 | May 22, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $40 | $19.84 | +101.61% | 1 | May 20, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Buy | $36 → $27 | $19.61 | +37.68% | 2 | May 16, 2025 | |
| ACRV Acrivon Therapeutics | Downgrades: Hold | n/a | $1.91 | - | 2 | May 16, 2025 | |
| ONCY Oncolytics Biotech | Downgrades: Hold | n/a | $1.38 | - | 2 | May 16, 2025 | |
| MURA Mural Oncology | Downgrades: Hold | n/a | $2.08 | - | 2 | Mar 25, 2025 | |
| CRVO CervoMed | Upgrades: Buy | $15 | $8.70 | +72.41% | 3 | Mar 13, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $10 | $3.71 | +169.54% | 1 | Mar 12, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $34 | $25.75 | +32.04% | 2 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $2.39 | +1,406.28% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $2.71 | +1,080.81% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.21 | - | 1 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $11.04 | -18.48% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $11.57 | +47.00% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $3.92 | +231.63% | 1 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $4 | $0.83 | +379.33% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.63 | - | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $5.31 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $26 | $5.90 | +340.68% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $24.00 | +191.67% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $99.39 | -89.94% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.83 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $17.00 | +370.59% | 1 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.66 | - | 2 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $4.04 | +7,820.79% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $810 | $5.44 | +14,789.71% | 1 | Feb 24, 2021 |
CG Oncology
Sep 8, 2025
Initiates: Buy
Price Target: $50
Current: $39.82
Upside: +25.57%
Protara Therapeutics
May 22, 2025
Initiates: Buy
Price Target: $21
Current: $4.96
Upside: +323.39%
ArriVent BioPharma
May 20, 2025
Initiates: Buy
Price Target: $40
Current: $19.84
Upside: +101.61%
Enliven Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $36 → $27
Current: $19.61
Upside: +37.68%
Acrivon Therapeutics
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.91
Upside: -
Oncolytics Biotech
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.38
Upside: -
Mural Oncology
Mar 25, 2025
Downgrades: Hold
Price Target: n/a
Current: $2.08
Upside: -
CervoMed
Mar 13, 2025
Upgrades: Buy
Price Target: $15
Current: $8.70
Upside: +72.41%
Nuvation Bio
Mar 12, 2025
Initiates: Buy
Price Target: $10
Current: $3.71
Upside: +169.54%
Beam Therapeutics
Mar 10, 2025
Upgrades: Buy
Price Target: $34
Current: $25.75
Upside: +32.04%
Feb 11, 2025
Upgrades: Buy
Price Target: $36
Current: $2.39
Upside: +1,406.28%
Jan 28, 2025
Initiates: Buy
Price Target: $32
Current: $2.71
Upside: +1,080.81%
Nov 1, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.21
Upside: -
Oct 31, 2024
Initiates: Buy
Price Target: $9
Current: $11.04
Upside: -18.48%
Oct 31, 2024
Initiates: Buy
Price Target: $17
Current: $11.57
Upside: +47.00%
Sep 17, 2024
Initiates: Buy
Price Target: $13
Current: $3.92
Upside: +231.63%
Sep 11, 2024
Maintains: Buy
Price Target: $6 → $4
Current: $0.83
Upside: +379.33%
Jul 1, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.63
Upside: -
May 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $5.31
Upside: -
Apr 17, 2024
Maintains: Buy
Price Target: $22 → $26
Current: $5.90
Upside: +340.68%
Apr 16, 2024
Initiates: Buy
Price Target: $70
Current: $24.00
Upside: +191.67%
Apr 11, 2024
Upgrades: Buy
Price Target: $10
Current: $99.39
Upside: -89.94%
May 23, 2023
Downgrades: Hold
Price Target: n/a
Current: $4.83
Upside: -
Apr 19, 2023
Initiates: Buy
Price Target: $80
Current: $17.00
Upside: +370.59%
Nov 16, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.66
Upside: -
Nov 8, 2022
Initiates: Buy
Price Target: $320
Current: $4.04
Upside: +7,820.79%
Feb 24, 2021
Initiates: Buy
Price Target: $810
Current: $5.44
Upside: +14,789.71%